Recent 8-K filings for PDEX
Highest-materiality recent filing
Pro-Dex Q2 net sales up 33% to $16.8M; EPS $0.61 vs $0.14
- Q2 net sales $16.8M (+33% YoY) driven by $3.1M shipment of next-gen orthopedic handpiece for largest customer.
- Net income $2.0M ($0.61 diluted) vs $0.5M ($0.14) prior year; gross margin 30% vs 22%.
-
Pro-Dex Q3 revenue record $19.9M; net income up to $3.9M on one-time gain
Q3 net sales record $19.9M, up 15% YoY; driven by $4.7M increase in largest customer's next-gen handpiece.
-
Pro-Dex increases CFO Alisha Charlton's base salary to $257,000
Base salary raised from $247,200 to $257,000 per year (approx. 4% increase).
-
Pro-Dex acquires Advanced Precision Machining for $8.65M; finances with UMB term loan
Total purchase price ~$8.65M: $6.65M cash at closing (funded by UMB Term Note D) + $2M subordinated note (8% interest, 63 months).
-
Pro-Dex Q2 sales up 11% to $18.7M; net income $0.66/share; eyes acquisition of supplier
Net sales $18.7M (+11% YoY) driven by $7.3M in next-gen orthopedic handpiece shipments offset by legacy declines.
-
Pro-Dex extends largest customer contract through 2028, grants CEO $225K bonus
Executed three-year contract amendment with largest customer, extending through Dec 31, 2028.
-
Compensation committee granted 1,000 restricted shares to CFO Alisha K. Charlton, vesting over five years.
-
Pro-Dex Q1 FY2026: sales +24% to $18.5M, EPS $1.40 incl. $3.3M unrealized gains
Net sales rose 24% YoY to $18.5M driven by resumed next-generation handpiece production for largest customer.
-
Full-year net sales $66.6M (+24% YoY), operating income $10.7M (+49%), net income $9.0M ($2.67 diluted EPS) vs $2.1M ($0.60).
-
Pro-Dex awards $120k in discretionary bonuses to CEO and CFO
CEO Richard Van Kirk receives $70k bonus for sales growth and FY2025 performance exceeding plan.
-
Pro-Dex changes auditor to Baker Tilly after Moss Adams merger
Moss Adams merged into Baker Tilly effective June 3, 2025; Baker Tilly appointed as successor independent auditor.
-
Pro-Dex Q3 net income $3.3M ($0.98/share), sales up 22% to $17.4M
Net sales rose 22% to $17.4M driven by $6.2M of next-gen orthopedic handpiece shipments.
-
Pro-Dex increases revolving credit line from $7M to $11M with UMB Bank
Revolving credit line raised to $11M (from $7M); $5M drawn and outstanding as of April 8, 2025.
-
Pro-Dex Q2 net sales up 33% to $16.8M; EPS $0.61 vs $0.14
Q2 net sales $16.8M (+33% YoY) driven by $3.1M shipment of next-gen orthopedic handpiece for largest customer.
-
Pro-Dex extends $7M revolving credit facility maturity to Dec 2026
Maturity extended from December 29, 2025 to December 29, 2026.
-
Pro-Dex grants restricted shares to CEO, CFO, directors, and employees under 2016 Plan
Compensation Committee approved restricted share grants on Nov 20, 2024 to non-employee directors and select employees.
-
All seven director nominees elected with 2.0M-2.3M votes for each; broker non-votes of 542,256.
-
Pro-Dex Q1 net sales up 25% to $14.9M; net income $2.5M vs loss prior year
Net sales $14.9M (+25% YoY); gross margin 35% (+4pp); operating income $3.0M (+64%).
-
Pro-Dex CEO awarded $70,000 discretionary bonus for Q1 FY2025 performance
Compensation Committee approved $70,000 discretionary cash bonus for CEO Richard L. Van Kirk.
-
Q4 net sales $15.0M (+41% YoY); operating income $2.4M (+46%); diluted EPS $0.46 vs $0.42.
-
Pro-Dex awards $120K in discretionary bonuses to CEO and CFO for FY2024 performance
CEO Richard L. Van Kirk receives $70,000 cash bonus based on sales growth and FY2024 financial performance exceeding plan.
-
Pro-Dex enters $5M Term Loan C to refinance revolving debt and fund stock buybacks
New $5M Term Loan C refinances $3M revolving balance; $2M+ available for stock repurchases under 10b5-1 plan.
-
Pro-Dex Q3 revenue up 9% to $14.3M; net income falls to $0.19 EPS on investment losses
Net sales $14.3M (+9% YoY); operating income $2.2M (+7%) driven by medical device revenue.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.60 · Most common event earnings